Pharmaceuticals that target the GLP-1 pathway are prescription drugs used for diabetes treatment that lead to significant weight loss and appetite reduction.

“There are a whole category of pharmaceuticals that's being developed right now that are in late-stage trials or are in use for the treatment of diabetes, which capitalize on this GLP-1 pathway. They go by various names. ... Semaglutide is the way I would pronounce it. In any case, this compound increases GLP-1. It's actually a GLP-1 analog in some cases and they go by various types of trade names. Again, semaglutide is the prescription version. It's the heavy artillery GLP-1 stimulant and, again, should be only explored with a prescription.”